Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2008

SmartCells’ Alliance with JDRF Kicks Off with $1M

  • The Juvenile Diabetes Research Foundation (JDRF) and SmartCells are partnering to advance the company’s SmartInsulin™ product. JDRF will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The collaboration will support milestone-based funding through proof-of-concept clinical trials.

    SmartInsulin is being developed as a once-daily, glucose-regulated subcutaneous insulin formulation for treating type 1 diabetes. “Our formulation is designed to address the most critical issue in diabetes treatment—achieving tight glucose control without inducing severe hypoglycemic episodes,” explains Todd C. Zion, Ph.D., president and CEO.

    The grant is part of JDRF’s Industry Discovery and Development Partnership Program, which supports companies developing drugs, treatments, and technologies to address type 1 diabetes and its complications. Other companies that have received support from JDRF include EpiVax and  Osiris.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »